Not Yet Recruiting
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
NCT07192237
- Conditions
- Acute Lymphoblastic Leukemia, Blinatumomab, Hematologic Diseases, +11 more
- Locations
-
- MD Anderson Cancer Center Houston, Texas, United States